Asian Journal of Research and Reports in Endocrinology

The Impact of Disease Duration on Sex Differences in Cardiometabolic Risk Factors in Type 2 Diabetic Patients on Metformin-glimepiride Oral Therapy

Martin Awe Akilla

Department of Medical Laboratory Technology, School of Applied Science and Art, Bolgatanga Technical University, Bolgatanga. Ghana.

Moses Banyeh *

Department of Biomedical Laboratory Science, School of Allied Health Sciences, University for Development Studies, Tamale. Ghana.

Ignatius Abowini Awinibuno Nchor

Directorate of Allied Health, Ministry of Health, Accra Ghana.

*Author to whom correspondence should be addressed.

---

Abstract

Aims: Patients with type 2 diabetes mellitus (T2DM) are commonly treated with metformin-glimepiride combination therapy. The relationship between disease duration and cardiometabolic risk factors among T2DM patients on metformin-glimepiride combination therapy may be moderated by sex. This, however, has not been investigated in the Ghanaian population.

Study Design: This was a cross-sectional study.

Place and Duration of Study: The study was conducted from January to December 2019 at the Bolgatanga Regional Hospital which is located in the Upper East region of Ghana.

Methodology: The study involved 163 patients with T2DM (Female=103 and Male=60) who were between the ages of 25 and 70 years. All the participants were receiving metformin-glimepiride combination oral therapy at the time of sampling. The participants were matched by age, duration of disease and age at the onset of T2DM. The blood pressure and anthropometric variables were measured after which fasting venous blood samples were collected and analyzed for lipids, insulin, glucose and C-reactive protein.

Results: There was a significant interaction between sex and the duration of T2DM on fasting plasma triglycerides level (P=0.003). The fasting plasma triglyceride reduced with the duration of T2DM but the reduction was more marked in males (adjR²=0.200) than females (adjR²= 0.001).

Conclusion: Fasting plasma triglyceride levels may be reduced with the duration of T2DM among patients on metformin-glimepiride combination therapy. However, this reduction is more pronounced in males than in the female. There is a need for sex-specific protocols for the control of plasma triglyceride levels among patients with T2DM who are on metformin-glimepiride combination therapy.

Keywords: Glimepiride, metformin, triglycerides, cardiovascular disease, diabetes mellitus, Ghana

---

---

---

References

Najim HD, Majeed IA, Rahmah AM. Effects of Metformin, glimepiride and their combination on glycemia and lipid profile of NIDDM patients-A study in Iraqis. Int J Adv Pharm Biol Chem. 2013;2:4688:2277.

Lebovitz HE. Insulin resistance– A common link between type 2 diabetes and cardiovascular disease. Diabetes Obes Metab. 2006;8(3):237-49. DOI: 10.1111/j.1463-1326.2005.00521.x, PMID 16634983.

de Marinis E, Martini C, Trentalance A, Pallottini V. Sex differences in hepatic regulation of cholesterol homeostasis. J Endocrinol. 2008;198(3):635-43. DOI: 10.1677/JOE-08-0242, PMID 18603607.

Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it’s not just about sex hormones. J Clin Endocrinol Metab. 2011;96(4):885-93. DOI: 10.1210/jc.2010-2061, PMID 21474685.

Palmisano BT, Zhu L, Eckel RH, Stafford JM. Sex differences in lipid and lipoprotein metabolism. Mol Metab. 2018;15:45-55. DOI: 10.1016/j.molmet.2018.05.008, PMID 29858147.

Bosi E. Metformin–the gold standard in type 2 diabetes: What does the evidence tell us? Diabetes Obes Metab. 2009;11;Suppl 2:3-8. DOI: 10.1111/j.1463-1326.2008.01031.x, PMID 19385978.

Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J Intern Med. 2004;256(1):1-14.

DOI: 10.1111/j.1365-2796.2004.01328.x, PMID 15189360.

Shimpi R, Patil P, Kuchake V, Ingle P, Surana S, Dighore P. Comparison of effect of metformin in combination with glimepiride and glibenclamide on glycaemic control in patient with type 2 diabetes mellitus. Int J Pharm Technol, (Research). 2009;1:50-61.

Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37(3):278-316. DOI: 10.1210/er.2015-1137, PMID 27159875.

Östgren CJ, Lindblad U, Ranstam J, Melander A, Råstam L, Skaraborg hypertension and diabetees project. Glycaemic control, disease duration and β‐cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg hypertension and diabetes project. Diabet Med. 2002;19(2):125-9. DOI: 10.1046/j.1464-5491.2002.00661.x, PMID 11874428.

GHS. Standard treatment Guidlines. Ghana National Drugs Program, Ministry of Health [online]. Accra, Ghana; 2017. [Cited May 10 2019]. Available:https://www.bing.com/search q=Ghana+health+services+treatment+protocol+for+type+2+diabetes&cvid=880d3bcdcdbb4cc99b6422d6209217eb&aqs=edge.0.69i59j69i57j69i59j69i61j69i60l2j69i65.4142j0j4&FORM=ANAB01&PC=U531

World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. World health organization; 1999.

Horáková D, Štěpánek L, Janout V, Janoutová J, Pastucha D, Kollárová H, et al. Optimal homeostasis model assessment of insulin resistance (HOMA-IR) cut-offs: A cross-sectional study in the Czech population. Medicina (Kaunas). 2019;55(5). DOI: 10.3390/medicina55050158, PMID 31108989.

Ingle PV, Talele DGS. Comparative effects of metformin in combination with glimepiride and glibenclamide on lipid profile in Indian patients with type 2 diabetes mellitus. Age (year, Mean, SD). 2011;47:45.

Das A, Datta S, Chakrabarty S, Begum SA, Dey SK, Mukherjee AK. An open-label, prospective, observational study of effects of metformin versus metformin plus glimepiride on plasma lipid profile in type ii diabetes mellitus patients in a Tertiary Care Teaching Hospital in Kolkata. JMSCR. 2018;6(7). DOI: 10.18535/jmscr/v6i7.144

Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010;6(2):225-35. DOI: 10.1517/17425250903512955, PMID 20055691.

Pradhan AD. Sex differences in the metabolic syndrome: Implications for cardiovascular health in women. Clin Chem. 2014;60(1):44-52. DOI: 10.1373/clinchem.2013.202549, PMID 24255079.

Meyer MR, Clegg DJ, Prossnitz ER, Barton M. Obesity, insulin resistance and diabetes: Sex differences and role of oestrogen receptors. Acta Physiol (Oxf). 2011;203(1):259-69. DOI: 10.1111/j.1748-1716.2010.02237.x, PMID 21281456.

Tramunt B, Smati S, Grandgeorge N, Lenfant F, Arnal JF, Montagner A, et al.Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia. 2020;63(3):453-61. DOI: 10.1007/s00125-019-05040-3, PMID 31754750.

Hemmingsen B, Gimenez-Perez G, Mauricio D, Roqué I Figuls M, Metzendorf MI, Richter B. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;12(12):CD003054.

DOI: 10.1002/14651858.CD003054.pub4, PMID 29205264.

Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, et al. Long-term sustainability of diabetes prevention approaches: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2017;177(12):1808-17. DOI: 10.1001/jamainternmed.2017.6040, PMID 29114778.